AZ/Daiichi Sankyo Enhertu Head-to-Head Phase 3 Clinical: Curative Effect Beats Roche Kadcyla

AstraZeneca and Daiichi Sankyo recently announced the detailed positive results of the head-to-head Phase 3 DESTINY-Breast03 trial at the 2021 European Society of Medical Oncology (ESMO) virtual conference.

Kadcyla is a targeted drug that has been approved for the treatment of the aforementioned HER2-positive breast cancer patients

The data released at the meeting showed that in the pre-specified interim analysis, the DESTINY-Breast03 trial reached the primary endpoint of progression-free survival (PFS): Compared with Kadcyla, Enhertu significantly reduced the risk of disease progression or death by 72% (HR= 0.

In terms of the key secondary endpoints of PFS assessed by the investigator, the median PFS of the Enhertu group was 3 times that of the Kadcyla group (25.

In addition, in terms of the overall survival (OS) of the key secondary endpoint: Compared with the Kadcyla group, the Enhertu group showed a strong trend of improvement (HR=0.

Compared with the Kadcyla group, the confirmed objective response rate (ORR) in the Enhertu group more than doubled (79.

In this trial, Enhertu's safety was consistent with previous clinical trials, and no new safety issues were found

DESTINY-Breast03 test results

According to the independent review committee, 27 cases (10.

In March 2019, AstraZeneca and Daiichi San reached a total value of US$6.

Enhertu is a new-generation ADC drug that combines trastuzumab (trastuzumab), a humanized monoclonal antibody targeting HER2 with a new topoisomerase 1 inhibitor exatecan derivative ( DX-8951 derivatives, DXd) are linked together, which can target the delivery of cytotoxic agents to cancer cells.

Up to now, Enhertu (5.

Breast cancer is the most common type of cancer in women and one of the leading causes of cancer-related deaths in women

Note: The original text has been deleted

Original source: Enhertu reduced the risk of disease progression or death by 72% vs.